This study published in the World Journal of Diabetes evaluates the effect on cardiovascular outcomes of sodium-glucose co-transporter-2 (SGLT2) inhibitors in a real world setting by analyzing electronic medical records.
Manfred Paul Stapff, CMO, TriNetX Inc., Cambridge, MA 02140, United States
World J Diabetes. Dec 15, 2018; 9(12): 252-257